Alnylam Pharmaceuticals this week announced that it has started a phase I trial of its subcutaneous TTR-mediated amyloidosis treatment ALN-TTRsc.
The study is being conducted in the UK and will examine single and multiple escalating doses of the drug in up to 40 healthy volunteers.
The trial’s primary endpoints are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum levels of the TTR protein. Data is expected to be available by mid-year, Alnylam said.
As previously disclosed, a phase II trial of ALN-TTRsc is slated to begin before the end of 2013, with a pivotal trial on track for 2014.